Trial Profile

A phase 1/2 study of ExoPTEN for the treatment of spinal cord injuries

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Phosphatase and tensin homolog siRNA loaded exosome therapy NurExone Biologic (Primary)
Indications Spinal cord injuries
Focus Adverse reactions; First in man; Therapeutic Use

30 May 2025 According to a NurExone media release, Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be presenting at the annual meeting of the American Spinal Injury Association, to discuss updates on the 2026 SCI Trial.
27 May 2025 According to a NurExone media release, Investigational new drug-enabling studies for ExoPTEN, NurExone's lead exosome-based therapy, is expected to enter first-in-human trials in 2026.
19 Sep 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com